


Common errors in meta-analysis

Lessons from the Cochrane Review Screening Programme

November 2017

Kerry Dwan

Trusted evidence. Informed decisions. Better health.





Objectives

The objectives of this workshop are to highlight common statistical errors made in Cochrane Systematic Reviews, and to provide practical, hands on learning and guidance to help authors and editors address these errors.


- Slides with examples
- Practical Exercises
- General Discussion



Poll

What are your roles in Cochrane?


- Editor
- Author
- Statistician
- Other
- No role in Cochrane yet





Common Errors

- Funny Looking Results
- Analyses
- Errors we may not see





FLR (Funny Looking Results)

- 1. Data entry errors/ transposition errors
- 2. Study weight at odd with sample size
- 3. Outliers
- 4. Study ID appearing more than once in a forest plot
- 5. Reporting at odds with forest plot



FLR #1 -Data Entry Error

	Experi			Experimental Control			Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Study 4	0.8	1.7	62	2	2.9	51	32.9%	-0.51 [-0.89, -0.14]	
Study 5	2.5	2	92	0.5	1.5	95	33.6%	1.13 [0.82, 1.44]	
Study 6	1.8	1.5	85	1	1.8	78	33.5%	0.48 [0.17, 0.79]	
Total (95% CI)			239			224	100.0%	0.37 [-0.52, 1.26]	
Heterogeneity: Tau ² :	= 0.59; Ch	ni² = 40	3.69, dt	f= 2 (P -	< 0.00	0001); I	²= 95%	-	
Test for overall effect	: Z = 0.82	(P = 0).41)					Favours [experimental] Favours [control]	


Poll

Which study do you think is probably erroneous?

- Study 4
- Study 5
- Study 6



FLR #1 -Data Entry Error




Study 4 Data

Measure	Baseline Mean (SD)	Placebo Mean (SD)	Clomipramine Mean (SD)	Haloperidol Mean (SD)	p
CARS	41.8 (7.1)	39.4 (7.0)	37.8 (8.7)	36.7 (6.1)	0.05^{b}
ESRS	6.6(6.7)	7.9(7.1)	10.3 (7.3)	7.8 (5.8)	0.35^{c}
DOTES	0.6 (2.2)	0.8 (1.7)	2.0 (2.9)	2.3(3.3)	0.07^{d}

TABLE 2. Comparison of placebo, clomipramine, and haloperidol with baseline for CARS, ESRS, and DOTES^a



FLR #2 – Study weight at odds with sample size



Poll


Which study do you think is probably erroneous?

- Study 1
- Study 2

Question: why? (type the answer in your question box)



FLR #3 – Outliers





FLR #4 – Study ID appearing >1 in a forest plot

Question: what is the problem with this? (type the answer in your question box)

Shudy or Subaroun	Mean	eatment			control	Total	Moinht	Std. Mean Difference	Std. Mean Difference
Study or Subgroup 1.2.1 Timepoint 1	mean	50	rotal	Mean	50	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Study 1	30	15.45	17	20	20.45	17	4.5%	-0.54 [-1.22, 0.15]	-
Subtotal (95% CI)	20	10.40	17	30	20.45	17	4.5%	-0.54 [-1.22, 0.15]	
Heterogeneity: Not ap	onlienble							served a second	25 V
Test for overall effect			25						
restion overall energy		0-0.1	*						
1.2.2 Timepoint 2									
Study 1	30	15.5	17	30	20.55	17	4.6%	0.00 [-0.67, 0.67]	+
Study 2	4.5	2.48	13	4.5	2.48	16	4.0%	0.00 [-0.73, 0.73]	+
Subtotal (95% CI)	12.22	-	30	100	-	33	8.6%	0.00 [-0.50, 0.50]	•
Heterogeneity: Tau* =	: 0.00: CH	hi [#] = 0.00	0. df=	1 (P = 1	00) P=	= 0%			
Test for overall effect					0.5	0.0305			
1.2.3 Timepoint 3									
Study 3	2.66	1.47	57	3.58	1.62	55	11.6%	-0.59 [-0.97, -0.21]	-
Study 4	2.89	1.59	88	3.49	1.41	90	16.0%	-0.40 [-0.69, -0.10]	*
Study 5	43.3	19.7	17	46.8	25.4	17	4.6%	-0.15 [-0.82, 0.52]	+
Subtotal (95% CI)			162			162	32.2%	-0.44 [-0.66, -0.22]	•
Heterogeneity: Tau ^a =	0.00; Ch	hi ² = 1.40	0, df=	2 (P = 0	.50); P =	= 0%			
Test for overall effect	Z = 3.88	(P = 0.0	001)						
1.2.4 Timepoint 4	382	1212121	12524	0.225-25	12/10/10	1. 1922	12022		
Study 2	4	2.97	13	3.54	3.13	16	4.0%	0.15 [-0.59, 0.88]	Ť
Study 3	2,89	1.81	57	3.28	1.48	55	11,9%	-0.23 [-0.61, 0.14]	1
Study 4	2.88	1.72	88	3.19	1.31	90	16.1%	-0.20 [-0.50, 0.09]	1
Subtotal (95% CI)		1000	158	DISC	110	161	32.0%	-0.18 [-0.40, 0.04]	1
Heterogeneity: Tau [#] = Test for overall effect				2 (P = 0	.65); P =	= 0%			
1.2.5 Timepoint 5									
Study 6	3.7	2.4	64	4.6	2.32	60	12.7%	-0.38 [-0.73, -0.02]	-
Subtotal (95% CI)	Q. F.	2.4	64	. 4.0	8.92	60	12.7%	-0.38 [-0.73, -0.02]	
Heterogeneity: Not ap	oplicable								65
Test for overall effect			(4)						
		10	8						
1.2.6 Trepoint 6									
Study 7	1.7	2	17	3.2	2.8	17	4.4%	-0.60 [-1.29, 0.09]	-
Subtotal (95% CI)			17			17	4.4%	-0.60 [-1.29, 0.09]	•
Heterogeneity: Not ap	oplicable								25
Test for overall effect	Z=1.71	(P = 0.0	9)						
2222282332									
1.2.7 Timepoint 7	1.1.45-1						-		
Study 8	11	9.3	8	53.9	23	7	1.2%	-2.37 [-3.78, -0.95]	
Subtotal (95% CI)	1725		8			7	1.2%	-2.37 [-3.78, -0.95]	
Heterogeneity: Not ap									
Test for overall effect	Z= 3.28	(P = 0.0	101)						
1.2.8 Timepoint 8									
Study 8	53.6	18	8	53.9	23	7	2.2%	-0.01 [-1.03, 1.00]	
Subtotal (95% CI)	33.0	10	8	33.8	23	7	2.2%	-0.01 [-1.03, 1.00]	
Heterogeneity: Not ap	onlicable					0.0	0.00	Succession and	ST
Test for overall effect			85						
1.2.9 Timepoint 9									
Study 8	51.6	22	8	53.9	23	7	2.2%	-0.10[-1.11, 0.92]	+
Subtotal (95% CI)	1.		8			7	2.2%	-0.10 [-1.11, 0.92]	•
Heterogeneity: Not ap	oplicable								
Test for overall effect			(5)						
		12 C	Baue						
			472			474	100.0%	-0.32 [-0.48, -0.17]	
Total (95% CI)			S. 1997					-0.55 [-0.40, -0.11]	
Total (95% Cl) Heterogeneity: Tau* =	0.02; CI	hi# = 16.1	S. 1997	13 (P	= 0.24);			-0.52 [-0.40, -0.11]	-10 -5 0 5 10



	Treatment Control					1	Std. Mean Difference	Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
Study 1	30	15.5	17	30	20.55	17	4.6%	0.00 [-0.67, 0.67]	+	
Study 1	20	15.45	17	30	20.45	17	4.5%	-0.54 [-1.22, 0.15]		
Study 2	4.5	2.48	13	4.5	2.48	16	4.0%	0.00 [-0.73, 0.73]	+	
Study 2	4	2.97	13	3.54	3.13	16	4.0%	0.15 [-0.59, 0.88]	+	
Study 3	2.89	1.81	57	3.28	1.48	55	11.9%	-0.23 [-0.61, 0.14]	-	
Study 3	2.66	1.47	57	3.58	1.62	55	11.6%	-0.59 [-0.97, -0.21]	+	
Study 4	2.89	1.59	88	3.49	1.41	90	16.0%	-0.40 [-0.69, -0.10]	•	
Study 4	2.88	1.72	88	3.19	1.31	90	16.1%	-0.20 [-0.50, 0.09]	•	
Study 5	43.3	19.7	17	46.8	25.4	17	4.6%	-0.15 [-0.82, 0.52]	+	
Study 6	3.7	2.4	64	4.6	2.32	60	12.7%	-0.38 [-0.73, -0.02]	-	
Study 7	1.7	2	17	3.2	2.8	17	4.4%	-0.60 [-1.29, 0.09]		
Study 8	11	9.3	8	53.9	23	7	1.2%	-2.37 [-3.78, -0.95]		
Study 8	51.6	22	8	53.9	23	7	2.2%	-0.10 [-1.11, 0.92]	+	
Study 8	53.6	18	8	53.9	23	7	2.2%	-0.01 [-1.03, 1.00]	+	
Total (95% CI)			472			471	100.0%	-0.32 [-0.48, -0.17]	•	
Heterogeneity: Tau ²	= 0.02; C	hi ^z = 16.	.17, df=	= 13 (P =	= 0.24);	l ² = 209	%	-		
Test for overall effec	•		•						-10 -5 Ó 5 10 Foreuro experimental. Foreuro control	
		,							Favours experimental Favours control	

Studies included multiple times



FLR #5 – Reporting at odds with forest plot

1.8 Adverse effects

	STR)	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
1.8.1 Drowsiness Chiron 2000 Subtotal (95% CI)	19	21 21	1	20 20		18.10 [2.67, 122.86] 18.10 [2.67, 122.86]	
Total events Heterogeneity: Not ap	19 nlicable		1				
Test for overall effect:		(P = 0.0)03)				
1.8.2 Loss of appetite	e						
Chiron 2000 Subtotal (95% CI)	7	21 21	0	20 20	8.3% <mark>8.3%</mark>	14.32 [0.87, 235.36] 14.32 [0.87, 235.36]	
Total events Heterogeneity: Not ap Test for overall effect:		(P = 0.0	0				
1.8.3 Loss of weight		•	,				
Chiron 2000 Subtotal (95% CI)	6	21 21	0	20 20		12.41 [0.74, 206.86] 12.41 [0.74, 206.86]	
Total events Heterogeneity: Not ap	6 plicable		0				
Test for overall effect:		(P = 0.0)8)				
1.8.4 Weight gain							
Chiron 2000 Subtotal (95% CI)	5	21 21	4	20 20	66.7% 66.7%	1.19 [0.37, 3.81] 1.19 [0.37, 3.81]	
Total events Heterogeneity: Not ap Test for overall effect:		(P = 0.7	4				
Total (95% CI)		. 84		80	100.0%	6.04 [2.67, 13.65]	
Total events	37		5		100.070	0.04 [2.07, 10.00]	
Heterogeneity: Chi ² = Test for overall effect: Test for subgroup diff	Z= 4.32	(P < 0.0	0001)		0.05), I² =	: 61.9%	0.01 0.1 1 10 100 More in placebo More in STP
Total events Heterogeneity: Chi ² = Test for overall effect:	9.36, df = Z = 4.32 (3 (P = (P < 0.0	0.02); I ² = 1001)	= 68%			

'Higher proportions of participants were reported to experience side effects in the treatment group compared with placebo (100% vs 25%; RR 6.04, 95% CI 2.67 to 13.65)'. Question: what is the issue here? (type the answer in your question

box)



FLR #5 – Reporting at odds with forest plot

'The confidence intervals for the estimated HR include large benefit and moderate harm of intervention (0.88; 95% CI 0.64 to 1.12), P = 0.43'

			Intervention	Control		Hazard Ratio	Hazar	d Ratio	
Study or Subgroup	Hazard Ratio	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Rando	m, 95% Cl	
Study 1	0.88	0.12	5472	3940	100.0%	0.88 [0.64, 1.12]			
Total (95% CI)			5472	3940	100.0%	0.88 [0.64, 1.12]		•	
Heterogeneity: Not ap Test for overall effect:	•	00001)			F	-2 -1 (avours experimental) 1 Favours cor	2 ntrol

Question: what is the issue here? (type the answer in your question box)



Analysis

1. Unit of analysis

- Crossover trials (Nolan et al. PLoS ONE 2016)
- Cluster trials (Richardson et al. PLoS ONE 2016)

2. Subgroups

- Post hoc, wrong analysis, incorrect interpretation
- Adequate number of studies, 10?
- Specify small number of characteristics in advance with rationale (Donegan et al. PLoS ONE 2016)

3. SMDs and MDs


- Used incorrectly, not often back transformed
- 4. Random effects versus fixed effects
 - Inconsistently used



1. Unit of analysis

Unit of analysis issues

We planned to take into account the level at which randomisation occurred, such as cross-over trials, cluster-randomised trials and multiple observations for the same outcome. In case of cross-over trials or cluster-randomised trials, we planned to extract estimates of effect that took into account the correlation of the measurements.




Footnotes

(1) Median values were reported, SDs values were calculated based on reported change in mean and P value

Unadjusted data from study reports used in analysis




Practical Exercise 1





Practical Exercise 1 - Feedback





Practical Exercise 1 – Solutions

Figure 1: outcome 1





Figure 2: outcome 2

	Supp	ort	Usual o	are		Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI		
Study 90	3	50	33	50	0.1%	0.09 (0.03, 0.28)	←		
Study 72	5	27	16	25	0.2%	0.29 [0.12, 0.67]	·		
Study 45	6	19	15	19	0.3%	0.40 [0.20, 0.81]			
Study 89a	6	22	20	23	0.3%	0.31 [0.16, 0.63]			
Study 79	17	60	22	22	0.5%	0.36 [0.22, 0.57]			
Study 3	20	33	26	157	0.6%	3.66 [2.34, 5.72]			
Study 74	15	21	17	20	0.9%	0.84 [0.61, 1.17]			
Study 67	36	80	26	30	1.1%	0.52 (0.39, 0.69)			
Study 63	38	69	48	81	1.1%	0.93 [0.70, 1.23]			
01-14-005	24	~~~	C 0	50	4.000	0.0010-10-0.700	I		



2. Comparing Subgroups

use a <u>formal statistical test</u> to compare subgroups




<u>Abstract</u>: Our Review suggests that (INTERVENTION) may have more beneficial effects in (SUBGROUP)

<u>PLS</u>: In the further analyses, there is evidence indicated that the effects of (INTERVENTION) in reducing (OUTCOME) rate may be different between (SUBGROUP 1) and (SUBGROUP 2), with more benefits observed in (SUBGROUP 1)




Practical Exercise 2






Practical Exercise 2 - Feedback





Practical Exercise 2 – Solutions




Main results

The effect of intervention X on reducing outcome A was uncertain due to the low quality of the evidence (RR 0.67, 95% CI 0.39 to 1.14; 605 participants; 4 studies). Subgroup analysis by type of intervention X provided limited evidence that X (b) may lower the risk of outcome A.



3. MDs and SMDs

"We will convert continuous outcome data into standardised mean differences (SMDs) and present with 95% CIs, as it is assumed that study authors will use different measurement scales. If continuous outcome data is recorded using the same measurement scale, data will be converted into mean differences (MDs) and presented with 95% Cis".




Question: what is the problem here? (type the answer in your question box)



4. Fixed Effect versus Random Effects

"We considered statistical heterogeneity between trials to be substantial if, following meta-analysis, I² was greater than 30% and either T² is greater than zero, or there was a low P-value (< 0.10) in the Chi² test for heterogeneity. If substantial heterogeneity was identified used the random-effects (RE) model instead of the fixed-effects (FE) model to pool data".



Question: what is the problem here? (type the answer in your question box)



Errors we may not see

- Have any papers been missed?
- Have the right results been copied from the papers?
- Have the standard deviations been confused with standard errors?

Question: Are there any other errors we may not see? (type suggestions in your question box)


Test drive

training.cochrane.org/common-errors





Final Tips






Tips for spotting errors

- Numbers that stand out (perfect homogeneity, single outlying results, sample size does not match with precision relative to other studies)
- For non-standard RCT designs evidence of how SEs were adjusted (check methods against plots).
- For primary outcomes select the biggest study or the one that has most weight and check the analysis results against the paper.
- For other outcomes pick a study entirely at random and check numbers used against what is available in published trial report or elsewhere. If authors have stated that they got unpublished data then move on to next study.



Discussion





References and resources

Nolan SJ, Hambleton I, Dwan K (2016) The Use and Reporting of the Cross-Over Study Design in Clinical Trials and Systematic Reviews: A Systematic Assessment. PLoS ONE 11(7): e0159014. https://doi.org/10.1371/journal.pone.0159014

Richardson M, Garner P, Donegan S (2016) Cluster Randomised Trials in Cochrane Reviews: Evaluation of Methodological and Reporting Practice. PLoS ONE 11(3): e0151818. <u>https://doi.org/10.1371/journal.pone.0151818</u>


Donegan S, Williams L, Dias S, Tudur-Smith C, Welton N (2015) Exploring Treatment by Covariate Interactions Using Subgroup Analysis and Meta-Regression in Cochrane Reviews: A Review of Recent Practice. PLoS ONE 10(6): e0128804. https://doi.org/10.1371/journal.pone.0128804

MECIR http://methods.cochrane.org/mecir

training.cochrane.org/common-errors




Practical Exercises 3 and 4 - Feedback





Practical Exercise 3 – Solutions



Note: Lower total scores indicate a better clinical result

	Experimental	Control		Mean Difference	Mean Difference					
Study or Subgroup	Mean SD To	otal Mean SD	Total Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl					
Brown 2003	19.1 21	145 16 22	146 12.2%	3.10 [-1.84, 8.04]						
Gilbert 1995	23.77 🤇 5.88 🚺	65 2.88 5.22	65 91.3%	0.89 [-1.02, 2.80]						
Smith 2015	31 17.21	42 24 17.21	62 6.5%	7.00 [0.26, 13.74]						
Total (95% CI)	:	252	273 100.0%	1.56 [-0.17, 3.28]	•					
Heterogeneity: Chi ² = 3.35, df = 2 (P = 0.19); l ² = 40% -20 -20 -10 0 10 20 Test for overall effect: Z = 1.77 (P = 0.08) Favours [experimental] Favours [control]										



Practical Exercise 4 – Solutions

	Expe	rimen	tal	C	ontrol		:	Std. Mean Difference	Std. Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl	ABCDEFGH
Study 1	0.07	0.3	69	-0.04	0.3	5	13.6%	0.36 [-0.55, 1.27]	+	
Study 2	-1.02	4.77	50	-5.93	4.57	52	14.8%	1.04 [0.63, 1.46]	-	•?•••
Study 3	3.02	0.08	62	2.59	0.08	40	13.8%	5.33 [4.49, 6.18]	()	•?•••
Study 4	-0.45	1.29	11	-1.11	1.45	9	13.6%	0.46 [-0.43, 1.36]	+- \ /	• ? • • • • • •
Study 5	-7.07	5.05	28	-7.85	3.59	26	14.6%	0.17 [-0.36, 0.71]	+ -	
Study 6	-0.5	4.3	37	-0.9	4.2	69	14.9%	0.09 [-0.31, 0.49]	+	•?•••
Study 7	0.31	3.08	31	0.06	2.85	41	14.7%	0.08 [-0.38, 0.55]	+	•?••?•
Total (95% Cl) Heterogeneity: Tau² =				df = 6 (P	< 0.00	242 0001); I	100.0 % ² = 96%	1.05 [0.04, 2.07]	-4 -2 0 2 4	-
Test for overall effect:	Z = 2.03	(P=0	1.04)						Favours [control] Favours [experime	nt]

Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Sample Size
- (H) Other bias



Practical Exercise 4 – Solutions

	Expe	erimen	ital	C	ontrol		:	Std. Mean Difference	Std. Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl	ABCDEFGH
Study 1	0.07	0.3	69	-0.04	0.3	5	7.8%	0.36 [-0.55, 1.27]		
Study 2	-1.02	4.77	50	-5.93	4.57	52	17.6%	1.04 [0.63, 1.46]		•?•••
Study 3	3.02	0.8	62	2.59	0.8	40	17.9%	0.53 [0.13, 0.94]	()	•?••••?•
Study 4	-0.45	1.29	11	-1.11	1.45	9	8.0%	0.46 [-0.43, 1.36]	↓ /	
Study 5	-7.07	5.05	28	-7.85	3.59	26	14.5%	0.17 [-0.36, 0.71]		
Study 6	-0.5	4.3	37	-0.9	4.2	69	18.0%	0.09 [-0.31, 0.49]	-	• ? • • • • ? •
Study 7	0.31	3.08	31	0.06	2.85	41	16.2%	0.08 [-0.38, 0.55]	+	•?•••
Total (95% CI)			288			242	100.0%	0.40 [0.10, 0.70]	•	
Heterogeneity: Tau² = Test for overall effect:				f= 6 (P =	= 0.03)	-4 -2 0 2 Favours [control] Favours [experim	4 anent]			

Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Sample Size
- (H) Other bias